NVNO Stock Overview
A clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
enVVeno Medical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.07 |
| 52 Week High | US$6.97 |
| 52 Week Low | US$2.45 |
| Beta | 1.21 |
| 1 Month Change | 0.66% |
| 3 Month Change | -4.95% |
| 1 Year Change | -34.82% |
| 3 Year Change | -53.83% |
| 5 Year Change | -80.31% |
| Change since IPO | -97.66% |
Recent News & Updates
Recent updates
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans
Nov 27
Here's Why We're Not Too Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Situation
Jun 26Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
Mar 07Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?
Aug 14Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?
Apr 22We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Dec 21enVVeno Medical: Unique Exposure To Venous Treatment Domain
Sep 23We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely
Aug 23enVVeno Medical reports Q2 results
Aug 03We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth
May 10We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate
Jan 25Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Sep 08Hancock Jaffe Laboratories finance chief sheds interim tag
Dec 31Hancock Jaffe approves 1:25 reverse stock split
Nov 27Shareholder Returns
| NVNO | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.3% | -2.1% | -2.8% |
| 1Y | -34.8% | 9.9% | 24.1% |
Return vs Industry: NVNO underperformed the US Medical Equipment industry which returned 9.9% over the past year.
Return vs Market: NVNO underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| NVNO volatility | |
|---|---|
| NVNO Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVNO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVNO's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 31 | Robert Berman | www.envveno.com |
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company’s lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI.
enVVeno Medical Corporation Fundamentals Summary
| NVNO fundamental statistics | |
|---|---|
| Market cap | US$52.96m |
| Earnings (TTM) | -US$21.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs NVNO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVNO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$21.24m |
| Earnings | -US$21.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NVNO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 08:21 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
enVVeno Medical Corporation is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Cohen | Ladenburg Thalmann & Company |